Working… Menu
Trial record 1 of 1 for:    CA224-047
Previous Study | Return to List | Next Study

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03470922
Recruitment Status : Recruiting
First Posted : March 20, 2018
Last Update Posted : September 1, 2020
Information provided by (Responsible Party):
Bristol-Myers Squibb

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 24, 2021
Estimated Study Completion Date : March 16, 2023